Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
| العنوان: | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
|---|---|
| المؤلفون: | Domenico Azzarello, Antonio Nesci, Valerio Nardone, Pierfrancesco Tassone, Diana Giannarelli, Amalia Luce, Luciano Mutti, Irene Di Meo, Alfonso Reginelli, Rocco Giannicola, Rita Emilena Saladino, Luigi Pirtoli, Daniele Caracciolo, Vito Barbieri, Maria Rosaria Rizzo, Pierosandro Tagliaferri, P. Correale, Pierpaolo Pastina, Giovanna Bianco, Caterina Romeo, Michele Caraglia, Salvatore Cappabianca, Antonio Giordano, Antonia Consuelo Falzea |
| المساهمون: | Nardone, V., Giannicola, R., Giannarelli, D., Saladino, R. E., Azzarello, D., Romeo, C., Bianco, G., Rizzo, M. R., Di Meo, I., Nesci, A., Pastina, P., Falzea, A. C., Caracciolo, D., Reginelli, A., Caraglia, M., Luce, A., Mutti, L., Giordano, A., Cappabianca, S., Pirtoli, L., Barbieri, V., Tassone, P., Tagliaferri, P., Correale, P. |
| المصدر: | Life Volume 11 Issue 11 Life, Vol 11, Iss 1235, p 1235 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Science, medicine.medical_treatment, Inflammation, Systemic inflammation, General Biochemistry, Genetics and Molecular Biology, Article, real-world evidence study, Atezolizumab, Internal medicine, medicine, Lung cancer, Ecology, Evolution, Behavior and Systematics, immunosenescence, business.industry, metastatic non-small-cell lung cancer, Paleontology, Immunotherapy, Immunosenescence, immune checkpoint blockade, medicine.disease, inflammatory markers, Immune checkpoint, age, Space and Planetary Science, Inflammatory marker, immunotherapy, Nivolumab, medicine.symptom, business |
| الوصف: | An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells. It has been speculated that a chronic status of systemic inflammation as well as the immunosenescence physiologically occurring in elderly patients may affect the efficacy of the treatment and the occurrence of irAEs. We performed a multi-institutional retrospective study aimed at evaluating the effects of these mAbs (nivolumab or atezolizumab) in 117 mNSCLC patients younger (90 cases) and older (27 cases) than 75 years in correlation with multiple inflammatory parameters (NLR, CRP, ESR, LDH and PCT). No differences were observed when the cohorts were compared in terms of the frequency of PFS, OS, inflammatory markers and immune-related adverse events (irAEs). Similarly, the occurrence of irAEs was strictly correlated with a prolonged OS survival in both groups. On the contrary, a negative correlation between the high baseline levels of inflammatory markers and OS could be demonstrated in the younger cohort only. Overall, PD-1/PD-L1-blocking mAbs were equally effective in young and elderly mNSCLC patients however, the detrimental influence of a systemic inflammation at the baseline was only observed in young patients, suggesting different aging-related inflammation immunoregulative effects. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2075-1729 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b90d15be9d66293659e0c07af4932c1Test http://europepmc.org/articles/PMC8621400Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1b90d15be9d66293659e0c07af4932c1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20751729 |
|---|